Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5

被引:10
|
作者
Finney, Joel [1 ]
Yang, Guang [1 ]
Kuraoka, Masayuki [1 ]
Song, Shengli [1 ]
Nojima, Takuya [1 ]
Verkoczy, Laurent [2 ]
Kitamura, Daisuke [3 ]
Haynes, Barton F. [1 ,4 ]
Kelsoe, Garnett [1 ,4 ]
机构
[1] Duke Univ, Dept Immunol, Durham, NC 27710 USA
[2] San Diego Biomed Res Inst, San Diego, CA 92121 USA
[3] Tokyo Univ Sci, Res Inst Biomed Sci, Noda, Chiba 2780022, Japan
[4] Duke Univ, Human Vaccine Inst, Durham, NC 27710 USA
来源
JOURNAL OF IMMUNOLOGY | 2019年 / 203卷 / 12期
基金
美国国家卫生研究院;
关键词
MONOCLONAL-ANTIBODIES; GENE REPLACEMENT; CLONAL DELETION; SELF-TOLERANCE; MEMBRANE; AUTOREACTIVITY; LYMPHOCYTES; ANTIGEN; MICE; IDENTIFICATION;
D O I
10.4049/jimmunol.1900069
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
2F5 is an HIV-1 broadly neutralizing Ab that also binds the autoantigens kynureninase (KYNU) and anionic lipids. Generation of 2F5-like Abs is proscribed by immune tolerance, but it is unclear which autospecificity is responsible. We sampled the BCR repertoire of 2F5 knock-in mice before and after the first and second tolerance checkpoints. Nearly all small pre-B (precheck-point) and 35-70% of anergic peripheral B cells (postcheckpoint) expressed the 2F5 BCR and maintained KYNU, lipid, and HIV-1 gp41 reactivity. In contrast, all postcheckpoint mature follicular (MF) B cells had undergone L chain editing that purged KYNU and gp41 binding but left lipid reactivity largely intact. We conclude that specificity for KYNU is the primary driver of tolerization of 2F5-expressing B cells. The MF and anergic B cell populations favored distinct collections of editor L chains; surprisingly, however, MF and anergic B cells also frequently expressed identical BCRs. These results imply that BCR autoreactivity is the primary determinant of whether a developing B cell enters the MF or anergic compartments, with a secondary role for stochastic factors that slightly mix the two pools. Our study provides mechanistic insights into how immunological tolerance impairs humoral responses to HIV-1 and supports activation of anergic B cells as a potential method for HIV-1 vaccination.
引用
收藏
页码:3268 / 3281
页数:14
相关论文
共 50 条
  • [1] How Tolerance Shapes the Development of the HIV-1 Broadly Neutralizing Antibody 2F5
    Finney, Joel T.
    Yang, Guang
    Kuraoka, Masayuki
    Nojima, Takuya
    Verkoczy, Laurent
    Kitamura, Daisuke
    Haynes, Barton F.
    Kelsoe, Garnett H.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [2] Exploiting Natural Cross-reactivity between HIV-1 p17 Protein and 2F5 Antibody to Induce Neutralizing Responses In Vivo
    Phelip, Capucine
    Paul, Stephane
    Terrat, Celine
    Bastide, Liza
    Ensinas, Agathe
    Bulens-Grassigny, Laura
    Jospin, Fabienne
    Guillon, Christophe
    Verrier, Bernard
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 324 - 324
  • [3] Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans
    Huettner, Isabella
    Krumm, Stefanie A.
    Serna, Sonia
    Brzezicka, Katarzyna
    Monaco, Serena
    Walpole, Samuel
    van Diepen, Angela
    Allan, Fiona
    Hicks, Thomas
    Kimuda, Simon
    Emery, Aidan M.
    Landais, Elise
    Hokke, Cornelis H.
    Angulo, Jesus
    Reichardt, Niels
    Doores, Katie J.
    CELL REPORTS, 2022, 38 (13):
  • [4] Kynureninase is the conserved self-antigen mimicked by the 2F5 Neutralizing Epitope of HIV-1 gp41
    Yang, Guang
    Holl, T.
    Liu, Yang
    Li, Yi
    Lu, Xiaozhi
    Nicely, Nathan
    Kepler, Thomas
    Alam, S.
    Liao, Hua-Xin
    Cain, Derek
    Spicer, Leonard
    VandeBerg, John
    Haynes, Barton
    Kelsoe, Garnett
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [5] Broadly neutralizing HIV-1 antibody reactivity in HIV tests: implications for diagnostics
    Smith, Tara
    Masciotra, Silvina
    Luo, Wei
    Sullivan, Vickie
    Switzer, William M.
    Johnson, Jeffrey A.
    Heneine, Walid
    AIDS, 2021, 35 (10) : 1561 - 1565
  • [6] Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies
    Yang, Guang
    Holl, T. Matt
    Liu, Yang
    Li, Yi
    Lu, Xiaozhi
    Nicely, Nathan I.
    Kepler, Thomas B.
    Alam, S. Munir
    Liao, Hua-Xin
    Cain, Derek W.
    Spicer, Leonard
    VandeBerg, John L.
    Haynes, Barton F.
    Kelsoe, Garnett
    JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (02): : 241 - 256
  • [7] Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids
    Apellaniz, Beatriz
    Garcia-Saez, Ana J.
    Huarte, Nerea
    Kunert, Renate
    Vorauer-Uhl, Karola
    Katinger, Hermann
    Schwille, Petra
    Nieva, Jose L.
    FEBS LETTERS, 2010, 584 (08) : 1591 - 1596
  • [8] Structural Constraints Imposed by the Conserved Fusion Peptide on the HIV-1 gp41 Epitope Recognized by the Broadly Neutralizing Antibody 2F5
    de la Arada, Igor
    Julien, Jean-Philippe
    de la Torre, Beatriz G.
    Huarte, Nerea
    Andreu, David
    Pai, Emil F.
    Arrondo, Jose L. R.
    Nieva, Jose L.
    JOURNAL OF PHYSICAL CHEMISTRY B, 2009, 113 (41): : 13626 - 13637
  • [9] De Novo Design and Biophysical Characterization of an Affinity-Enhanced Protein Displaying the Structure of the Broadly Neutralizing HIV-1 2F5 Antibody Epitope
    Viana, Isabelle Freire Tabosa
    Nascimento, Eduardo
    Craigo, Jodi
    Krieger, Marco
    Mailliard, Robbie
    Dhalia, Rafael
    Lins, Roberto
    Marques, Ernesto T. A.
    BIOPHYSICAL JOURNAL, 2016, 110 (03) : 346A - 346A
  • [10] Structure-guided Alterations of the gp41-directed HIV-1 Broadly Neutralizing Antibody 2F5 Reveal New Properties Regarding its Neutralizing Function
    Guenaga, Javier
    Wyatt, Richard T.
    PLOS PATHOGENS, 2012, 8 (07): : 28